You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 7, July 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters to the Editor
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Substance Abuse/ Alcoholism
 •Statistics and Research Methods
 •Psychopharmacology
 •Drug Therapy
 •Public Health
 •Alert me on articles by topic

Lack of Information in Naltrexone Study—Reply

Sandra D. Comer, PhD; Maria A. Sullivan, MD, PhD; Elmer Yu, MD; Jami L. Rothenberg, PhD; Herbert D. Kleber, MD; Kyle Kampman, MD; Charles Dackis, MD; Charles P. O’Brien, MD

Since this article does not have an abstract, we have provided the first 124 words of the full text and any section headings.

In reply

In response to Dr Rastegar, here is the flow diagram (Figure) showing the number of patients assessed for eligibility and the number excluded from our study1 of injectable, sustained-release naltrexone for the treatment of opioid dependence.


 
Figure appears in full text version.
Figure. Flow diagram for study of injectable, sustained-release naltrexone for the treatment of opioid dependence. ITT indicates intention to treat.



AUTHOR INFORMATION
Correspondence: Dr Comer, The New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, Unit 120, New York, NY 10032 (sdc10@columbia.edu).

Financial Disclosure: None reported.

1. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry. 2006;63(2):210-218. FREE FULL TEXT

Arch Gen Psychiatry. 2007;64(7):865.


RELATED LETTER

Lack of Information in Naltrexone Study
Darius A. Rastegar
Arch Gen Psychiatry. 2007;64(7):865.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Injectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence: A Randomized, Placebo-Controlled Trial
Sandra D. Comer, Maria A. Sullivan, Elmer Yu, Jami L. Rothenberg, Herbert D. Kleber, Kyle Kampman, Charles Dackis, and Charles P. O’Brien
Arch Gen Psychiatry. 2006;63(2):210-218.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.